仟源医药: 关于向激励对象首次授予限制性股票的公告

Core Viewpoint - Shanxi Qianyuan Pharmaceutical Group Co., Ltd. has approved the 2025 Restricted Stock Incentive Plan, granting 7.95 million shares of restricted stock at a price of 5.60 yuan per share to 171 eligible incentive objects on August 8, 2025 [1][11]. Summary by Sections Incentive Plan Overview - The total number of restricted stocks to be granted under the incentive plan does not exceed 9.15 million shares, accounting for 3.68% of the company's total share capital [2]. - The first grant involves 7.95 million shares, which is 86.89% of the total grant amount [10]. - The lock-up periods for the granted restricted stocks are set at 12, 24, and 36 months [2]. Performance Assessment Criteria - The performance assessment for the first grant period requires a net profit growth rate of no less than 25.43% in 2025 compared to 2024 [5]. - For the second grant period in 2026, the required growth rate is 71.04%, and for the third grant period in 2027, it is 133.96% [6][7]. Decision-Making Process - The decision-making process for the incentive plan has been completed, with necessary approvals obtained from the board and the compensation and assessment committee [9][11]. - The plan has been publicly disclosed for 10 days without any objections [9]. Legal and Financial Opinions - Legal opinions confirm that the incentive plan complies with relevant laws and regulations, and the conditions for granting the restricted stocks have been met [12][13]. - The independent financial advisor has also affirmed that the plan's implementation does not harm the interests of the company and its shareholders [12][13]. Financial Impact - The implementation of the restricted stock incentive plan is expected to have a limited impact on the company's financial status and operating results [11][12]. - The funds raised from the stock grant will be used to supplement the company's working capital [12].